IN-VITRO AND MOLECULAR DOCKING STUDIES OF SEVEN SELECTED MYRTACEAE PLANTS FOR NEURAMINIDASE ACTIVITY

by

ASHRAF AHMED ALI ABDUSALAM

Thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy

September 2016
IN-VITRO AND MOLECULAR DOCKING STUDIES OF SEVEN SELECTED MYRTACEAE PLANTS FOR NEURAMINIDASE ACTIVITY

ASHRAF AHMED ALI ABDUSALAM

UNIVERSITI SAINS MALAYSIA

2016
ACKNOWLEDGEMENT

First and foremost, I would like to give my warmest and greatest thanks to the Almighty Allah, who gave me the courage and strength to completing this project.

Second I would like to extend my thanks and appreciation to my supervisor associate Professor Dr. Nornisah Binti Mohamed for her full cooperation and encouragement motivation and enormous knowledge for helping me to make this work come true. Her understanding, kindness, expertise in guiding students, helped me greatly in overcoming the difficulties encountered during the course of my study and in completing the thesis. Her wonderful personality, will continue to influence and shape my behavior throughout my life.

My gratitude also goes to my co-supervisors Professor Dr. Hasnah Binti Osman and Dr. Ezatul Ezleen Kamarulzaman for their guidance, advice and support.

I would like to acknowledge the School of Pharmaceutical Sciences (Dean, academic and technical staff ) for allowing me to utilize all the necessary facilities to enable to complete this study.

I appreciate the help from the all group members of Pharmaceutical Design and Simulation laboratory (PhDs) and to my fellow lab mates in School of Pharmaceutical Science Universiti Sains Malaysia, especially Muhammad Fakhrul.
Last but not least, I would like to express my appreciation to my dear parents, my brother and sisters who always give me a prayer and blessing to finish my study.

Finally, my deep and special thanks are addressed to my lovely wife Dr. Gazala Ben-Hander and Estabrak and Ahmad my daughter and son.

(الحمد لله رب العالمين)
TABLE OF CONTENTS

Acknowledgment .............................................................................................................. ii

Table of Contents ................................................................................................................ iv

List of Tables .......................................................................................................................... xiii

List of Figures .......................................................................................................................... xvi

List of Symbols and Abbreviations ......................................................................................... xx

Abstrak ................................................................................................................................ xxiii

Abstract ................................................................................................................................. xxvi

CHAPTER ONE: INTRODUCTION ......................................................................................... 1

1.1 The influenza A viruses ................................................................................................. 1

1.2 Influenza pandemics ...................................................................................................... 2

1.3 Swine influenza virus (SIV) .......................................................................................... 3

1.4 Life cycle of influenza A virus ....................................................................................... 4

1.5 Sialic acid ......................................................................................................................... 6

1.6 Neuraminidase NA ........................................................................................................ 7

1.7 Neuraminidase inhibitors (NAIs) .................................................................................. 8

1.8 Neuraminidase active Site ............................................................................................ 10

1.9 Natural products ........................................................................................................... 12

1.9.1 Family of Myrtaceae .................................................................................................. 14

1.9.1(a) *Psidium guajava* .................................................................................................. 15

1.9.1(a)(i) General introduct ............................................................................................... 15

1.9.1(a)(ii) Traditional medicinal uses of *Psidium guajava* .............................................. 16

iv
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.9.1(a)(iii)</td>
<td>Chemical constituents of <em>Psidium guajava</em></td>
<td>18</td>
</tr>
<tr>
<td>1.9.1(a)(iv)</td>
<td>Essential oils of <em>Psidium guajava</em></td>
<td>24</td>
</tr>
<tr>
<td>1.9.1(a)(v)</td>
<td>Biological activities of <em>Psidium guajava</em></td>
<td>29</td>
</tr>
<tr>
<td>1.9.1(b)</td>
<td><em>Syzygium cumini</em></td>
<td>30</td>
</tr>
<tr>
<td>1.9.1(b)(i)</td>
<td>General introduction</td>
<td>30</td>
</tr>
<tr>
<td>1.9.1(b)(ii)</td>
<td>Traditional medicinal uses of <em>Syzygium cumini</em></td>
<td>31</td>
</tr>
<tr>
<td>1.9.1(b)(iii)</td>
<td>Chemical constituents of <em>Syzygium cumini</em></td>
<td>31</td>
</tr>
<tr>
<td>1.9.1(b)(iv)</td>
<td>Essential oils of <em>Syzygium cumini</em></td>
<td>31</td>
</tr>
<tr>
<td>1.9.1(b)(v)</td>
<td>Biological activities of <em>Syzygium cumini</em></td>
<td>32</td>
</tr>
<tr>
<td>1.9.1(c)</td>
<td><em>Syzygium grande</em></td>
<td>33</td>
</tr>
<tr>
<td>1.9.1(c)(i)</td>
<td>General introduction</td>
<td>33</td>
</tr>
<tr>
<td>1.9.1(c)(ii)</td>
<td>Traditional medicinal uses of <em>Syzygium grande</em></td>
<td>34</td>
</tr>
<tr>
<td>1.9.1(c)(iii)</td>
<td>Chemical constituents of <em>Syzygium grande</em></td>
<td>34</td>
</tr>
<tr>
<td>1.9.1(c)(iv)</td>
<td>Essential oils of <em>Syzygium grande</em></td>
<td>34</td>
</tr>
<tr>
<td>1.9.1(c)(v)</td>
<td>Biological activities of <em>Syzygium grande</em></td>
<td>34</td>
</tr>
<tr>
<td>1.9.1(d)</td>
<td><em>Syzygium jambos</em></td>
<td>36</td>
</tr>
<tr>
<td>1.9.1(d)(i)</td>
<td>General introduction</td>
<td>36</td>
</tr>
<tr>
<td>1.9.1(d)(ii)</td>
<td>Traditional medicinal uses of <em>Syzygium jambos</em></td>
<td>36</td>
</tr>
<tr>
<td>1.9.1(d)(iii)</td>
<td>Chemical constituents of <em>Syzygium jambos</em></td>
<td>36</td>
</tr>
<tr>
<td>1.9.1(d)(iv)</td>
<td>Essential oils of <em>Syzygium jambos</em></td>
<td>37</td>
</tr>
<tr>
<td>1.9.1(d)(v)</td>
<td>Biological activities of <em>Syzygium jambos</em></td>
<td>37</td>
</tr>
<tr>
<td>1.9.1(e)</td>
<td><em>Syzygium samarangense</em></td>
<td>38</td>
</tr>
</tbody>
</table>
1.9.1(e)(i) General introduction ................................. 38
1.9.1(e)(ii) Traditional medicinal uses of *Syzygium samarangense* ................................. 39
1.9.1(e)(iii) Chemical constituents of *Syzygium samarangense* ................................. 39
1.9.1(e)(iv) Essential oils of *Syzygium samarangense* ................................. 39
1.9.1(e)(v) Biological activities of *Syzygium samarangense* ................................. 40

1.9.1(f) *Syzygium malaccense* cultivated jambu bol ................................. 41
1.9.1(f)(i) General introduction ................................. 41
1.9.1(f)(ii) Traditional medicinal uses of *Syzygium malaccense* cultivated jambu bol ................................. 42
1.9.1(f)(iii) Chemical constituents of *Syzygium malaccense* cultivated jambu bol ................................. 42
1.9.1(f)(iv) Essential oils of *Syzygium malaccense* cultivated jambu bol ................................. 42
1.9.1(f)(v) Biological activities of *Syzygium malaccense* cultivated jambu bol ................................. 43

1.9.1(g) *Syzygium malaccense* cultivated jambu susu ................................. 44
1.9.1(g)(i) General introduction ................................. 44
1.9.1(g)(ii) Essential oil of *Syzygium malaccense* cultivated jambu susu ................................. 45
1.9.1(g)(iii) Biological activities of *Syzygium malaccense* cultivated jambu susu ................................. 45

1.10 Separation Techniques ................................. 46
1.10.1 Thin Layer Chromatography (TLC) ................................. 46
1.10.2 Column Chromatography (CC) ................................. 47
1.11 Essential oil (CC) ................................. 47
1.11.1 Methods for analyzing essential oil ................................. 48
1.11.1(a) Gas chromatography…………………………………… 48
1.11.1(b) Gas chromatography-mass spectrometry (GC-MS)…… 48

1.12 Molecular docking………………………………………………………… 49

1.13 Problem statements……………………………………………………… 52

1.14 Objectives of the research……………………………………………… 53

**CHAPTER TWO: ISOLATION, CHARACTERIZATION AND BIOASSAY**

**OF THE FRACTIONS AND ISOLATED COMPOUND**

2.1 Introduction ………………………………………………………………… 55

2.2 Materials and methods …………………………………………………… 57

2.2.1 Plant material …………………………………………………………… 58

2.2.2 Instrumentations………………………………………………………… 59

2.2.2(a) X-ray Crystallographic analysis…………………………………… 59

2.2.2(b) Turner biosystems Modulus Microplate reader and GLOMAX multi detection system (Promega) ... 59

2.2.2(c) Nuclear magnetic resonance (NMR) spectroscopy……… 60

2.2.2(d) Liquid Chromatography- Mass-Spectroscopy. ………… 60

2.2.2(e) High Performance Liquid Chromatography………………… 60

2.2.2(f) Infrared (IR) Spectroscopy……………………………………… 60

2.2.2(g) Gas Chromatography-Mass Spectroscopy………………… 61

2.2.3 Extraction and fractionations of four fruits and seven leaves of plants……………………………………………………………………… 61

2.2.3(a) Extraction of fruits …………………………………………………… 61

2.2.3(b) Fractionation of fruits ……………………………………………… 61

2.2.3(c) Extraction of leaves………………………………………………… 62

2.2.3(d) Fractionations of leaves……………………………………………. 62
2.2.3(e) Extraction of fruit for semi-prep HPLC ...................... 62

2.2.4 Isolation and purification of active compounds from fruit and leaves of Psidium guajava ................................. 63

2.2.4(a) Isolation of compounds from of Psidium guajava fruit using column chromatography .............................. 63

2.2.4(b) Isolation of compounds from of Psidium guajava leaves using column chromatography .............................. 65

2.2.5 Studies of neuraminidase Inhibitory Assay (MUNANA Assay) ...... 66

2.2.5(a) Preparation of stock solution ..................................... 66

2.2.5(a)(i) 325 mM MES ...................................................... 66

2.2.5(a)(ii) 100 mM CaCl2 .................................................. 67

2.2.5(a)(iii) 1M Glycine ...................................................... 67

2.2.5(b) Preparation of working solution .................................... 67

2.2.5(b)(i) 32.5 mM MES Buffer .......................................... 67

2.2.5(b)(ii) Stop solution ...................................................... 67

2.2.5(c) Preparation of substrate, enzyme and inhibitors ............... 68

2.2.5(c)(i) MUNANA substrate .............................................. 68

2.2.5(c)(ii) Neuraminidase enzymes ......................................... 68

2.2.5(c)(iii) Preparation of inhibitors (plant extracts, fractions and compounds) ................................................... 68

2.2.5(d) Neuraminidase inhibition assay protocol ......................... 69

2.3 Results and discussion ...................................................... 70

2.3.1 Yield of extracts and fractions ......................................... 70

2.3.1(a) Fruit MeOH extracts ............................................... 70

2.3.1(b) Fractions of fruit MeOH extract .................................... 71
2.3.1(c) Leaves MeOH extracts................................. 72
2.3.1(d) Fractions of leaves MeOH extract....................... 73
2.3.2 Process of the choose the active fraction for isolation ......... 74
2.3.3 NA inhibition for methanolic crude extracts.................... 75
   2.3.3(a) Fruit MeOH extract.................................... 75
   2.3.3(b) Leave MeOH extract................................... 76
2.3.4 NA inhibition for the fractions of seven varieties............. 77
   2.3.4(a) Bacterial NA inhibition assay ......................... 77
   2.3.4(b) H1N1 NA % inhibition assay............................. 81
2.3.5 Charactrization of isolated compounds from ethyl acetate fraction of Psidium guajava fruit.............................. 91
   2.3.5(a) Compound ETO1 ...................................... 91
   2.3.5(b) Compound ETO2 ...................................... 98
2.3.6 Characterization of isolated compounds from Psidium guajava fruit using semi-prep HPLC.................................. 101
   2.3.6(a) Compound PG1 .......................................... 102
   2.3.6(b) Compound PG2 .......................................... 106
2.3.7 Characterization of isolated compounds from ethyl acetate fraction of Psidium guajava leave.................................. 111
   2.3.7(a) Compound BF2 .......................................... 111
   2.3.7(b) Compound BF6 .......................................... 117
2.3.8 NA inhibition assay for isolated compounds (bacteria and H1N1 virus)................................................................. 123
2.4 Conclusion...................................................................... 126
CHAPTER THREE: ESSENTIAL OIL ANALYSIS AND NEURAMINIDASE INHIBITION ACTIVITY

3.1 Introduction ........................................................................................................ 128

3.2 Materials and methods..................................................................................... 129
  3.2.1 Collection of plant material.......................................................................... 129
  3.2.2 Extraction of essential oil............................................................................ 129
  3.2.3 GC-MS and head-space condition............................................................... 130
  3.2.4 Retention index calculation........................................................................ 131
  3.2.5 Identification of essential oil component................................................... 132

3.3 Results and discussion .................................................................................... 132
  3.3.1 Percentage yield of the essential oils......................................................... 132
  3.3.2 Essential oil analysis.................................................................................. 133
    3.3.2(a) Identification of chemical constituents of *Psidium guajava*.............. 133
    3.3.2(b) Identification of chemical constituents of *Syzygium cuminii*........... 137
    3.3.2(c) Identification of chemical constituents of *Syzygium grande*............. 141
    3.3.2(d) Identification of chemical constituents of *Syzygium malaccense* cultivated jambo bol.......................... 143
    3.3.2(e) Identification of chemical constituents of *Syzygium jambos*............. 144
    3.3.2(f) Identification of chemical constituents of *Syzygium samarangense* .... 146
    3.3.2(g) Identification of chemical constituents of *Syzygium malaccense* cultivated jambo susu......................... 149
  3.3.3 Evaluation of neuraminidase inhibition (MUNANA Assay)..................... 152
    3.3.3(a) Inhibition against *Clostridium perfringens* Neuraminidase Enzyme........ 152
3.4 Conclusions .............................................................................................................. 156

CHAPTER FOUR: IN SILICO MOLECULAR DOCKING ANALYSIS OF COMPOUNDS FROM ESSENTIAL OIL OF Syzygium malaccense cultivated jambu bol, Syzygium jambos, Syzygium malaccense cultivated jambu susu AND ISOLATED COMPOUNDS FROM Psidium guajava AS POSSIBLE NEURAMINIDASE H1N1 INHIBITOR.

4.1 Introduction .............................................................................................................. 157

4.2 Materials and Methods .......................................................................................... 158

4.2.1 Material ................................................................................................................. 158

4.2.2 Preparation of ligands .......................................................................................... 158

4.2.3 Protein preparation ............................................................................................... 159

4.2.4 Determination of active site ................................................................................... 159

4.2.5 Molecular Docking Simulation ............................................................................. 159

4.3 Results and discussion ........................................................................................... 161

4.3.1 Control docking of the conservative binding pocket using oseltamivir .................. 161

4.3.2 Control docking of the adjacent binding pocket (150-cavity) reported compound .... 162

4.3.3 Oseltamivir ............................................................................................................. 162

4.3.4 Compound NSC164640 ....................................................................................... 163

4.3.5 Molecular docking of the compounds isolated from Psidium guajava .................. 165

4.3.5(a) Molecular docking of the isolated compounds interact with the conservative active site ........................................................................................................... 166

4.3.5(b) Molecular docking of the isolated compounds interact with adjacent active site (150-cavity) ................................................................. 171

4.3.6 Molecular docking of compounds identified from active essential oils ............... 174
LIST OF TABLES

Table 1.1 Ethnomedical uses of *Psidium guajava*. 17
Table 2.1 Solvent, chemicals and reagent used. 57
Table 2.2 Voucher number of the seven selected plants. 59
Table 2.3 Yields of MeOH extracts of fruits. 71
Table 2.4 List of fraction from fruit, solvent used and amount obtained. 72
Table 2.5 List of leaves MeOH extract. 73
Table 2.6 Yield of fractions from MeOH extracts of leaves. 74
Table 2.7 IC\textsubscript{50} of MeOH extract of one fruit and seven leaves. 87
Table 2.8 IC\textsubscript{50} of fractions of one fruit and seven leaves. 87
Table 2.9 Percentage of inhibition of MeOH extract of one fruit and seven leaves at 250 μg mL\textsuperscript{-1}. 88
Table 2.10 Percentage of inhibition for fractions of one fruit and seven leaves. 90
Table 2.11 Comparison of the $^{13}$C-NMR spectral data (CD\textsubscript{3}OD 500 and 125MHz) of compound ETO1 with some available data in the literature. 95
Table 2.12 Crystal data and structure refinement details for ETO1 96
Table 2.13 Geometry parameter, bond lengths (Å) and angle (°) of ETO1 97
Table 2.14 Crystallographic date of compound ETO2 99
Table 2.15 Geometry parameter, bond lengths (Å) and angles (°) of ETO2 100
Table 2.16 Comparison of the $^{13}$C-NMR spectral data (CD\textsubscript{3}OD 500 and 125 MHz) of compound PG1 with some available data in the literature 106
Table 2.17 Comparison of the $^{13}$C-NMR spectral data (C5D5N 500 and 125 MHz) of compound PG2 with some available data in the literature

Table 2.18 Comparison of the $^{13}$C-NMR spectral data (C5D5N 500 and 125MHz) of compound BF2 with some available data in the literature

Table 2.19 Comparison of the $^{13}$C-NMR spectral data (C5D5N 500 and 125 MHz) of compound BF6 with some available data in the literature

Table 2.20 The inhibition and IC50 for the isolated compounds.

Table 3.1 Essential oil yield of seven species.

Table 3.2 Composition of the volatile oil from fruits of *Psidium guajava* L. (components listed in order of elution on the HP-5 column).

Table 3.3 Comparsion the obtained terenoild with previously reported of *psidium guajava*.

Table 3.4 Chemical composition of volatile oil from leaves of *Syzygium cuminii*. (Components listed in order of elution on the HP-5 column).

Table 3.5 Chemical composition of volatile oil from leaves of *Syzygium cuminii*.

Table 3.6 Chemical composition of volatile oil from leaves of *Syzygium grande*. (Components listed in order of elution on the HP-5 column).

Table 3.7 Chemical composition of volatile oil from leaves of *Syzygium malaccense* cultivated - Jambu bol (components listed in order of elution on the HP-5 column).

Table 3.8 Chemical composition of volatile oil from leaves of *Syzygium jambos* (components listed in order of elution on the HP-5 column).

Table 3.9 Chemical composition of volatile oil from leaves of *Syzygium samarangens* (components listed in order of elution on the HP-5 column).
Table 3.10  Chemical composition of volatile oil from leaves of *Syzygium malacanse* cultivated jambo susu (components listed in order of elution on the HP-5 column).

Table 3.11  IC₅₀ value for crude oil extract against NA from H1N1.

Table 4.1  Summary of hydrogen bonds between oseltamivir and important interacting amino acid residue of 3TI6.

Table 4.2  Summary of the interaction between compound NSC164640 and the amino acid residue at the 150-cavity in the 3TI6.

Table 4.3  The binding energy and types of interaction of the isolated compounds.

Table 4.4  The binding energy and types of interaction of the isolated compounds.

Table 4.5  Binding energies and interaction of ten compounds from essential oil with the protein.
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Schematic diagram of influenza A viruses (Horimoto and Kawaoka, 2005).</td>
</tr>
<tr>
<td>1.2</td>
<td>Schematic diagram of the influenza viral life cycle (Das et al., 2010).</td>
</tr>
<tr>
<td>1.3</td>
<td>Structure of N-acetyl and N-glycolylneuraminic acids. These SA differ at position 5 of the pyranose ring. N-Acetylneuraminic acid is the precursor of N-glycolylneuraminic acid; enzymatic hydroxylation of the former results in the latter.</td>
</tr>
<tr>
<td>1.4</td>
<td>Structures of (a) peramivir, (b) laninamivir, (c) Oseltamivir, (d) Zanamivir, (e) DANA.</td>
</tr>
<tr>
<td>1.5</td>
<td>The neuraminidase active site The conserved NA residues (R118, D151, R152, R224, E227, E276, R292, and R371).</td>
</tr>
<tr>
<td>1.6</td>
<td><em>Psidium guajava</em> plants (a) flower, (b) leaves (c) fruit and (d) tree.</td>
</tr>
<tr>
<td>1.7</td>
<td><em>Syzygium cumini</em> plants (a) flower, (b) fruit, (c) leaves and (d) tree.</td>
</tr>
<tr>
<td>1.8</td>
<td><em>Syzygium grande</em> plants (a) flower, (b) fruit, (c) leaves and (d) tree.</td>
</tr>
<tr>
<td>1.9</td>
<td><em>Syzygium jambos</em> plants (a) flower, (b) fruit, (c) leaves and (d) tree.</td>
</tr>
<tr>
<td>1.10</td>
<td><em>Syzygium samarangense</em> plants (a) flower, (b) fruit, (c) leaves and (d) tree.</td>
</tr>
<tr>
<td>1.11</td>
<td><em>Syzygium malaccense</em> cultivated jamb bol (a) flower, (b) fruit, (c) leaves and (d) tree.</td>
</tr>
<tr>
<td>1.12</td>
<td><em>Syzygium malaccense</em> cultivated jamb susu plants (a) flower, (b) fruit, (c) leaves and (d) tree.</td>
</tr>
<tr>
<td>2.1</td>
<td>Flow chart of research activities.</td>
</tr>
<tr>
<td>2.2</td>
<td>Isolation scheme of <strong>ETO1</strong> and <strong>ETO2</strong> compounds.</td>
</tr>
<tr>
<td>2.3</td>
<td>Isolation scheme of <strong>BF2</strong> and <strong>BF6</strong> compounds.</td>
</tr>
</tbody>
</table>
Figure 2.4  Illustration of 96-well Microplate for NA Assay. Well with red colors represent serial dilution of NA, while well with green green color represent negative control (without NA) and yellow colors represent blank control.

Figure 2.5  Bacterial NA % inhibition activity of fruits MeOH extract.

Figure 2.6  Bacterial NA % inhibition activity of leave MeOH extract.

Figure 2.7  Bacterial NA % inhibition activity of *P. guajava* fruit MeOH extract and fractions.

Figure 2.8  Bacterial NA % inhibition activity of (a) P. guajava (b) *S. cumini* (c) *S. grande* (d) *S. jambos* (e) *S. samarangense* (f) *S. malaccense* cultivated jambu bol (g) *S. malaccense* cultivated jambu susu leaves MeOH extracts and fractions.

Figure 2.9  H1N1 NA % inhibition activity of *P. guajava* fruit MeOH extracts.

Figure 2.10  H1N1 NA % inhibition activity of (a) *P. guajava* (b) *S. cumini* (c) *S. grande* (d) *S. jambos* (e) *S. samarangense* (f) *S. malaccense* cultivated jambu bol (g) *S. malaccense* cultivated jambu susu leaves MeOH extracts and fractions.

Figure 2.11  $^{13}$C-NMR spectrum (CD$_3$OD 125 MHz) of compound **ETO1**.

Figure 2.12  $^{13}$C-NMR spectrum (CD$_3$OD125 MHz) of compound **ETO1**.

Figure 2.13  X-ray crystal structure of Kojic acid.

Figure 2.14  X-ray crystal structure of 1,3-benzothiazole-oxalic acid (2/1).

Figure 2.15  The HPLC chromatogram separation of MeOH extract from *Psidium guajava*.

Figure 2.16  $^1$H-NMR spectrum (CD$_3$OD 500 MHz) of compound **PG1**.

Figure 2.17  $^{13}$C-NMR spectrum (CD$_3$OD 125 MHz) of compound **PG1**.

Figure 2.18  $^1$H-NMR spectrum (C$_5$D$_5$N 500 MHz) of compound **PG2**.

Figure 2.19  $^{13}$C-NMR spectrum (C$_5$D$_5$N 125 MHz) of compound **PG2**.

Figure 2.20  $^1$H-NMR spectrum (C$_5$D$_5$N 500 MHz) of compound **BF2**.
Figure 2.21  $^{13}$C-NMR spectrum (C$_5$D$_5$N 125 MHz) of compound BF$_2$.  115
Figure 2.22  $^1$H-NMR spectrum (C$_5$D$_5$N 500 MHz) of compound BF$_6$.  119
Figure 2.23  $^{13}$C-NMR spectrum (C$_5$D$_5$N 125 MHz) of compound BF$_6$.  120
Figure 2.24  Bacterial NA % inhibition activity of isolated compounds from P. guajava.  153
Figure 2.25  Virus H1N1 % inhibition activity of isolated compounds from P. guajava.  124

Figure 3.1  Hydrodistillation apparatus used for extraction of essential oil.  130
Figure 3.2  Percentage of inhibition between Neuraminidase against essential oil extracts.  150
Figure 3.3  Percentage of inhibition between Neuraminidase from H1N1 against essential oil extracts.  154
Figure 3.4  Inhibition activity compounds identified from essential oil against of NA.  153

Figure 4.1  The grid box of covering the active site of 3TI6.  160
Figure 4.2  Superimposition between the receptor-ligand complex of docked conformation A interaction (yellow) and the crystal structure (Red) of NA, H1N1 B.  161
Figure 4.3  The docked conformation of oseltamivir and 3TI6 suggested by molecular docking. Green dashed lines represented H-bonds between oseltamivir and important amino acids residues of 3TI6.  163
Figure 4.4a  3D representation of the compound NSC164640 attached to the 150-cavity in the 3TI6.  164
Figure 4.4b  2D representation of the compound NSC164640 attached to the 150-cavity in the 3TI6.  165
Figure 4.5  Superimposition of the oseltamivir red with the three isolated compounds in the active site with DANA (blue) ursolic acid (yellow) ursolic aldehyde (light blue) 1,3-benzothiazole-oxalic acid (purple).  168
Figure 4.6 2D representation of the three isolated compounds and dana in the 3TI6 active site (a) DANA, (b) 1,3-benzothiazole-oxalic acid, (c) ursolic acid and (d) ursolic aldehyde.

Figure 4.7 Superimposition of the three isolated compounds that attached to the 150-cavity kojic acid (yellow) gallic acid (pink) quercetin (purple) and the OTV (red) attached to the conservative active site.

Figure 4.8 2D representation of the three isolated compounds and in the 3TI6 active site (a) quercetin, (b) gallic acid and (c) kojic acid.

Figure 4.9 2D representation of the ten identified compounds and in the 3TI6 active site (a) γ-terpinene, (b) humulene oxide (c) borneol (d) carvacrol (e) furfural (f) Isopulegol (g) methyl salicylate (h) Safranal (i) tau-cadinol and (j) Curcumene.
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg</td>
<td>Microgram</td>
</tr>
<tr>
<td>µM</td>
<td>Micromolar</td>
</tr>
<tr>
<td>$^{13}$C NMR</td>
<td>Carbon Nuclear magnetic Resonance</td>
</tr>
<tr>
<td>1D NMR</td>
<td>One Dimensional Nuclear magnetic Resonance</td>
</tr>
<tr>
<td>$^1$H NMR</td>
<td>Proton Nuclear magnetic Resonance</td>
</tr>
<tr>
<td>$^1$H-$^{13}$C HMBC</td>
<td>Heteronuclear Multiple-Bond Correlation</td>
</tr>
<tr>
<td>$^1$H-$^{13}$C HSQC</td>
<td>Heteronuclear Single-Quantum Correlation</td>
</tr>
<tr>
<td>$^1$H-$^1$H COSY</td>
<td>Homonuclear Correlation Spectroscopy</td>
</tr>
<tr>
<td>2D NMR</td>
<td>Two Dimensional Nuclear magnetic Resonance</td>
</tr>
<tr>
<td>Ala</td>
<td>Alanine</td>
</tr>
<tr>
<td>Arg</td>
<td>Arginine</td>
</tr>
<tr>
<td>Asn</td>
<td>Asparagine</td>
</tr>
<tr>
<td>Asp</td>
<td>Aspartic acid</td>
</tr>
<tr>
<td>BuoH</td>
<td>Butanol</td>
</tr>
<tr>
<td>CADD</td>
<td>Computer aided drug design</td>
</tr>
<tr>
<td>CC</td>
<td>Column chromatography</td>
</tr>
<tr>
<td>CHCl$_3$</td>
<td>Chloroform</td>
</tr>
<tr>
<td>d</td>
<td>Doublet</td>
</tr>
<tr>
<td>dd</td>
<td>Doublets of doublet</td>
</tr>
<tr>
<td>$ddd$</td>
<td>Doublets of doublet of doublet</td>
</tr>
<tr>
<td>DEPT NMR</td>
<td>Distortionless Enhancement by Polarization Transfer</td>
</tr>
<tr>
<td>EtoAc</td>
<td>Ethyl acetate</td>
</tr>
<tr>
<td>FT-IR</td>
<td>Fourier Transform Infrared</td>
</tr>
<tr>
<td>Glu</td>
<td>Glutamic acid</td>
</tr>
<tr>
<td>Gly</td>
<td>Glycine</td>
</tr>
<tr>
<td>HA</td>
<td>Hemagglutinin.</td>
</tr>
<tr>
<td>HS-GC/MS</td>
<td>HeadSpace Gas Chromatography Mass Spectrometry</td>
</tr>
<tr>
<td>Hz</td>
<td>Hertz</td>
</tr>
<tr>
<td>Symbol</td>
<td>Term</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>IC&lt;sub&gt;50&lt;/sub&gt;</td>
<td>Half-maximal inhibitory concentration</td>
</tr>
<tr>
<td>Lys</td>
<td>Lysine</td>
</tr>
<tr>
<td>m</td>
<td>Multiplet</td>
</tr>
<tr>
<td>m/z</td>
<td>Mass/charge</td>
</tr>
<tr>
<td>M1</td>
<td>Matrex</td>
</tr>
<tr>
<td>M2</td>
<td>Ion channel</td>
</tr>
<tr>
<td>MES</td>
<td>2-(N-Morpholino)EthaneSulfonic Acid</td>
</tr>
<tr>
<td>Methanol-&lt;i&gt;d&lt;/i&gt;5</td>
<td>Deuterated Methanol</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>MHz</td>
<td>Mega Hertz</td>
</tr>
<tr>
<td>MS</td>
<td>Mass spectrscopy</td>
</tr>
<tr>
<td>MUNANA</td>
<td>2′-(4-methylumbelliferyl)-α-d- N-acetylneuraminic acid</td>
</tr>
<tr>
<td>NA</td>
<td>Neuraminidase</td>
</tr>
<tr>
<td>NAI</td>
<td>Neuraminidase inhibitor</td>
</tr>
<tr>
<td>Neu5AC</td>
<td>N-acetylneuraminic acid</td>
</tr>
<tr>
<td>NP</td>
<td>nucleoprotein</td>
</tr>
<tr>
<td>PA</td>
<td>Viral RNA polymerase</td>
</tr>
<tr>
<td>PB1</td>
<td>Viral RNA polymerase</td>
</tr>
<tr>
<td>PB2</td>
<td>Viral RNA polymerase</td>
</tr>
<tr>
<td>PDB</td>
<td>Protein Data Bank</td>
</tr>
<tr>
<td>PTLC</td>
<td>Preparative Thin Layer Chromatography</td>
</tr>
<tr>
<td>Pyridine-&lt;i&gt;d&lt;/i&gt;5</td>
<td>Deuterated Pyridine</td>
</tr>
<tr>
<td>s</td>
<td>Singlet</td>
</tr>
<tr>
<td>SEMI-PREP</td>
<td>Semi Preparative High Performance Liquid Chromatography</td>
</tr>
<tr>
<td>HPLC</td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Serine</td>
</tr>
<tr>
<td>SPE</td>
<td>Solid phase microextraction</td>
</tr>
<tr>
<td>t</td>
<td>Triplet</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin Layer Chromatography</td>
</tr>
<tr>
<td>Tyr</td>
<td>Tyrosine</td>
</tr>
<tr>
<td>v/v</td>
<td>Volume/volume</td>
</tr>
<tr>
<td>Symbol</td>
<td>Definition</td>
</tr>
<tr>
<td>--------</td>
<td>------------------</td>
</tr>
<tr>
<td>w/v</td>
<td>Weight/volume</td>
</tr>
<tr>
<td>δ</td>
<td>Chemical shift</td>
</tr>
</tbody>
</table>
KAJIAN IN-VITRO DAN PENDOKAN MOLEKUL TUJUH TUMBUHAN MYRTACEAE TERPILIH UNTUK AKTIVITI NEURAMINIDASE

ABSTRAK

dan buah-buahan) daripada *P. guajava* untuk menghasilkan satu sebatian baru, 1,3-benzotiazol-asid oksalik dan lima sebatian yang telah dikenali, asid kojik, asid galik, kuersetin, asid ursolik dan ursolik aldehid. Kebanyakan daripada ekstrak mempamerkan perencatan yang bagus, buah *P. guajava* 89% dan tujuh daun yang menpunyai kadar perencatan antara 70 hingga 89% bagi *C. perfringens*. Bagi fraksi yang lain, perencatan antara 12.2 hingga 97% terhadap NA daripada *C. perfringens* sementara 12.6 hingga 97.9% terhadap NA daripada H1N1. Tiga pati minyak menunjukkan perencatan tinggi sehingga 57.8, 88.7 dan 91.2% dalam kalangan tujuh pati minyak. IC\textsubscript{50} bagi dua sebatian terpencil, kuersetin adalah 229 µM, asid galik adalah 187 µM dan DANA 4.3 µM untuk NA bakteria, dan kuersetin 127 µM, asid galik 258 µM dan DANA 3.9 µM untuk NA virus H1N1. Pelbagai sebatian utama telah dikenalpasti daripada setiap varieti adalah 20.7% α-pinena daripada *P. guajava*, 25.1% Z-β-osimena daripada *S. cumini*, 33.1% δ-terpinena daripada *S. samarangense*, (Z)-3-heksanol 23.5% daripada *S. malaccense* jambu susu dan 62.5%, 20.5% dan 23.0% β-kariofilena masing-masing daripada *S. grande*, *S. malaccense* jambu bol dan *S. Jambos*. Pendokan molekul *in silico* sebatian terpencil daripada *P. guajava* dan sebatian yang dikenal pasti daripada minyak pati aktif telah dikaitkan dengan keputusan eksperimen. Semua sebatian mempamerkan interaksi dengan protein sasaran pada dua tapak mengikat berbeza, iaitu tapak aktif konservatif dan poket bersebelahan (kaviti 150). Hubungan antara *in silico* dan keputusan eksperimen menunjukkan bahawa aktiviti yang diperolehi bukan disebabkan oleh sebatian tunggal tetapi dari kesan sinergi, yang mana semua sebatian menyumbang untuk merencat neuraminidase. Kesimpulannya ekstrak mentah, fraksi, tiga daripada tujuh minyak
pati tumbuh-tumbuhan terpilih menunjukkan perencatan neuraminidase yang baik dan boleh menjadi sumber perencat neuraminidase.
IN-VITRO AND MOLECULAR DOCKING STUDIES OF SEVEN SELECTED MYRTACEAE PLANTS FOR NEURAMINIDASE ACTIVITY

ABSTRACT

Influenza A virus cause severe health problems to humans and several animal species which could result in morbidity and mortality in infected patients. Oseltamivir (Tamiflu) and zanamivir (Relenza) are two current drug used NA inhibitors that have been approved by the Food and Drug Administration (FAD, USA). However, due to the emergence of virus resistance to these drugs, there is an urgent need to discover an alternative neuraminidase inhibitors. The present study was undertaken to investigate the neuraminidase inhibition activity of seven selected plants that belong to the family of Myrtaceae; Psidium guajava, Syzygium cumini, Syzygium grande, Syzygium jambos, Syzygium malaccense cultivated jambu bol, Syzygium samaranges, and Syzygium malaccense cultivated jambu susu. The plants were extracted using methanol and fractionated using n-hexane, chloroform, ethyl acetate and butanol. Essential oils from leaves of seven selected plants were isolated by hydrodistillation and analyzed by head-space chromatography–mass spectrometry. The crude extract, fractions, compounds and essential oil were subjected to neuraminidase inhibition assay against Clostridium perfringens and H1N1 neuraminidase enzyme. Molecular docking using Autodocktools 4.2 were applied against the active site of neuraminidase H1N1 protein (PDB code: 3TI6) for the isolated and identified compounds from essential oil. The isolation was done from the ethyl acetate fraction of (leave and fruit) of P. guajava to yield one new compound 1,3-benzothiazole-oxalic acid and five
known compounds kojic acid, gallic acid, quercetin, ursolic acid and ursolic aldehyde. Good inhibition exhibited by most of the extracts, *P. guajava* fruit 89% and seven leaves ranging from 70 to 89% against *C. perfringens*. For the other fractions the inhibition ranged from 12.2 to 97% against NA from *C. perfringens* while 12.6-97.9% against NA from H1N1. Three essential oils showed high inhibition up to 57.8, 88.7 and 91.2% among the seven oils. The IC$_{50}$ of two isolated compounds quercetin was 229 µM, gallic acid was 187 µM and DANA 4.3 µM for the bacterial NA, and quercetin was 127 µM, gallic acid was 258 µM and DANA 3.9 µM for the NA H1N1 virus. Different major compounds identified in essential oil from each variety were 20.7% α-pinene in *P. guajava*, 25.1% Z-β-ocimene in *S. cumini*, 33.1% δ-terpinene in *S. samarangense*, (Z)-3-hexanol (23.5%) in *S. malaccense* cultivated jambu susu and 62.5%, 20.5% and 23.0% β-caryophyllene in *S. grande*, *S. malaccense* cultivated jambu bol and *S. Jambos*, respectively. The *in silico* molecular docking of isolated compounds from *P. guajava* and identified compounds from active essential oil were correlated with the experimental results. All the compounds exhibited interactions with the target protein at two different binding sites, namely, conservative active site and adjacent pocket (150-cavity). The correlation between the *in silico* and experimental results revealed that the obtained activity was not due to a single compound but from a synergistic effect, where all the compounds contributed to inhibit neuraminidase. In conclusion crude extracts, fractions, three out of seven essential oils of selected plants showed good neuraminidase inhibition and could be source of neuraminidase inhibitors.
CHAPTER ONE

INTRODUCTION

1.1 The influenza A viruses

The human-human transmission rate of the influenza virus A (H1N1) virus and their effects on human health attracted global attention in 2009. Influenza A viruses are isolated from numerous host species, such as marine mammals, horses, pigs, domestic birds, humans, and dogs (Webster et al., 1992). Influenza A viruses belong to the Orthomyxoviridae family and cause infrequent epidemics that usually result in increased death rates compared with seasonal influenza epidemics. These viruses have an RNA genome consisting of eight gene segments (Knipe et al., 2007; Wright et al., 2007) with two neuraminidase (NA) and a hemagglutinin (HA) as surface glycoproteins in the envelope (Lamb et al., 2001; Wright et al., 2001). Influenza A viruses are sorted into antigenic HA and NA subtypes. A total of 16 antigenic HA (H1–H16) and 9 NA (N1–N9) subtypes have been confirmed. H1N1, also called swine flu, consists of an H1 subtype HA and an N1 subtype NA (Schwahn et al., 2010). H3N2, H2N2, and H1N1 are considered the most important influenza A subtypes that infect humans during seasonal epidemics (Taubenberger et al., 2005). Influenza A viruses contain a genome consisting of eight segments involving a negative-sense, single-stranded RNA that encodes one or two proteins Figure 1.1.
1.2 Influenza pandemics

Influenza viruses cause global pandemics as well as repeated epidemics. In the 20th century, three major worldwide pandemics of influenza occurred at different interval in 1918, 1957, and 1968 (Taubenberger and Morens, 2006; Kilbourne, 2006). Spanish flu in 1918 was the most devastating pandemic that caused the death of 50 million people (Johnson and Mueller, 2002). The subsequent epidemics in 1957 occurred in Asia and Hong Kong flu pandemic of 1968; these two epidemics were milder, together caused a total of approximately two million deaths (Kilbourne, 2006). An important number of infected people would be detected resulting from the recently emerged H1N1 influenza virus and spread in many worldwide locations. In the
southwestern United States and Mexico 2009 new influenza A (H1N1) has been reported (Pan *et al.*, 2010). During the epidemic 2009 H1N1 the new strain of swine flu (hosted by pigs) attracted the attentions of most of the organizations, because this epidemic gain the ability of transfer from human to human.

### 1.3 Swine influenza virus (SIV)

A global influenza preparedness has been developed by World Health Organization (WHO), this plan used to define the pandemic stages which can be used as national measures before and during the pandemic. Concerning the swine influenza (H1N1) pandemic, the WHO raised alert levels according to the different H1N1 phases, namely phases 4, 5, and 6, on 27 April 2009, 29 April 2009, and 11 June 2009 respectively, these grouped into six-phases, phase 1-3 correlate with preparedness these including the capacity development and the response planning activities, while or phases 4-6 gave clear signal the need for serious response and more mitigation efforts.. Afterward, the WHO declared a full-blown influenza pandemic. Laboratories showed genuine cases of H1N1 reported from more than 214 countries in June 2010, with the casualties reaching 18,156 (WHO, 2009).

The pandemic H1N1 virus that spread in 2009 comprised various re-assorted viral genes from different sources. The virus was introduced to populations in 1998 from the avian virus with a North American lineage; this H1N1 virus consisted of two polymerase genes, eight segmented genomic RNAs, PA, and PB2 (Krause *µ*, 2010). Two different surface glycoproteins, NA and HA (Lamb and Krug, 2001; Wright and Webster, 2001), have important protective immunity within a host (Garten *et al.*, 2009).
This unique genetic combination may contribute to the improved fitness of the H1N1 in humans and its human-to-human transmissibility. No molecular functions have been shown before to confer the increased human-to-human transmissibility of the 2009 H1N1.

1.4 Life cycle of influenza A virus

The HA protein is critical for binding cellular receptors and fusing viral and endosomal membranes (Figure 1.2) (Das et al., 2010). The life cycle of the influenza A virus is divided into different stages: (1) viral entry to the host cell, (2) entry of viral ribonucleoprotein complex (vRNP) into the nucleus, (3) transcription and replication of the viral genome, (4) vRNP exportation from the nucleus (5) assembly, and then (6) budding at the plasma membrane of the host cell (Samji, 2009).

Fig. 1.2 Schematic diagram of the influenza viral life cycle (Das et al., 2010).
Influenza is spread via tiny droplets expelled through coughing or sneezing, thus can be easily inhaled thereby transmitting the disease. Once the virus has entered the host within the respiratory tract, particularly in the nose, mouth and throat, it will fuse to the plasma membrane of permissive cells lining in the respiratory tract. The projecting spikes on the viral lipid membrane known as hemagglutinin (HA) bind to sialic acid (SA) of the host cell's membrane. Two major linkages between SA and the carbohydrates which are important for the HA specificity is the α (2, 3) and α (2, 6) found in different species (Samji, 2009). Humans influenza recognize α (2, 6) linkages, avian influenza; α (2, 3) linkages while swine influenza recognize both linkages (Skehel and Wiley, 2000). This explains the importance of swine being a good mixing vessel for avian and human influenza viruses, hence producing dangerous pathogenic viruses.

After the attachment, receptor mediated endocytosis occurs and the virus is engulfed by the cell in an endosome at low pH of around 5 to 6. The acidic environment of the endosome induces conformational change in HA, bringing both the viral and endosomal membranes into contact with each other (Skehel and Wiley, 2000; Huang et al., 2003) and also opens up the M2 ion channel that acts as a proton selective ion channel, thus acidifies the viral core (Pinto and Lamb, 2006; Holsinger et al., 1994).

The viral constituents (vRNP) will then be released into the cytoplasm and migrate through the cytoplasm to the cell's nucleus. Viral transcription and replication occurs in the nucleus. The influenza viral genome is made up of negative sense strands of RNA and converted into a positive sense RNA for the genome to be transcribed.
The virus replicates its genome and forms new gene particles (Samji, 2009). New genes and proteins then migrate from the nucleus through the cytoplasm and to the cell membrane. The newly fanned viral begin to bud through the host cell's plasma membrane to form viral particles and eventually released into the extracellular environment to invade new cells (Scheiffele et al., 1999). The new viral particles are coated with sialic (neuraminic) acid (SA), the same substance that bound them to the exterior of the cell they had invaded (Samji, 2009; Scheiffele et al., 1999). The nascent viruses would stick to the membrane of the cell in which they had been formed, thus, unable to separate and travel to other cells in the respiratory tract.

The HA spike of one virus could stick to the SA coating of another, thereby causing viral aggregation and impeding the capability of the viruses to spread to, and invade, new cells. However, NA molecules, which are also part of the wrapping on the newly formed viral particles, cleave viral SA, thereby freeing the viruses from the host cell and from each other (Samji, 2009; Von Itzstein and Thomson, 2009). Drug that blocked the action of viral NA would thus prevent the escape of newly formed viruses from the host cells and thus preclude viral spread to other cells. This is the main reason as to why NA is taken as a drug target for developing agents in influenza virus drug discovery.

### 1.5 Sialic acid

Sialic acid (SA) is a common term for nine-carbon acidic amino sugars (5-amino-3,5-dideoxy-D-glycero-D-galacto-nonulosonic acid). Two new compounds, namely, N-glycolylneuraminic acid and N-acetyleneuraminic acid (Neu5Ac), are obtained by substituting the N-glycolyl group and N-acetyl with the amino group in
SA (Figure 1.3). The hydroxyl group can be substituted with phosphate, methyl, sulfate, or lactoyl residues (Suzuki et al., 2000). Human influenza viruses preferably bind to the sialic acid-α2,6-galactose SAα2,6Gal linkage, whereas equine and avian influenza viruses preferably bind to the (SAα2,3Gal) linkage (Connor et al., 1994).

![Fig. 1.3](image)

**Fig. 1.3** Structure of (a) N-acetyl and (b) N-glycolylneuraminic acids. These SA differ at position 5 of the pyranose ring. N-Acetylenuraminic acid is the precursor of N-glycolyneuraminic acid; enzymatic hydroxylation of the former results in the latter.

### 1.6 Neuraminidase NA

Influenza A viruses carry two surface glycoproteins, namely, HA and NA. Both proteins recognize the same host cell molecule, that is, SA and Neu5Ac, which are found as the terminal carbohydrate unit of the upper respiratory tract and lung-associated glycoconjugates (Von Itzstein and Thomson, 2009). NA encodes six RNA segments and is known as the second major surface antigen of virions. NA acts as a pair of biological scissors clipping Neu5Ac residues, thus facilitating movement and viral release (Von Itzstein and Thomson, 2009). The NA morphology can be divided into three domains: the cytoplasmic domain of six amino acids, the N-terminal hydrophobic domain, and the actual stalk domain (Colman, 1994). The cytoplasmic domain contains six amino acids completely conserved in the NA of influenza A. This
condition is essential for NA inclusion into virions and for the assembly of the influenza A virus.

Scientists have found nine different NAs (N9). However, only N1 and N2 are important in human infection, whereas the other NAs have only been found in seven animals. Neuraminidase is the major surface protein of the influenza virus that extracellularly acts by cleaving the terminal neuraminic acid from cellular receptors recognized by the HA. According to phylogenetic studies, the neuraminidase of the influenza virus is divided into two groups. Group one consist of N1, N4, N5, and N8, whereas the other group consist of N2, N3, N6, N7, and N9 (Gong et al., 2007).

The neuraminidase plays an extremely important role in the pathogenesis of viral infection. That is, it facilitates the release of newly formed virions from the host cell surface to the neighbor cells that facilitated the spread of the virus. NA acts as a receptor-destroying enzyme in the influenza virus by removing the terminal SA of a viral receptor (De Clercq, 2006).

1.7 Neuraminidase inhibitors (NAIs)

Inhibitors block the active site of the neuraminidase and then prevent the release and spread of new virions. After infection, the patient should take an antiviral drug during the early stage if possible to achieve an effective treatment. Antiviral drugs are important role in the management of infection caused by the seasonal influenza virus. Adamantanes (M2 ion channel blockers) and NA inhibitors (NAIs) are two classes of antiviral drugs licensed to prevent and treat infections caused by the influenza A virus (Moscona, 2008). The first inhibitor analog of SA is 2,3-
didehydro-2-deoxy-\textit{N}-acetylneuraminic acid or Neu5Ac2en (DANA) Figure 1.4 (Meindl \textit{et al.}, 1974).

The only two drugs approved by the Food and Drug Administration, oseltamivir and zanamivir currently effective for the treatment of influenza infections, the seasonal influenza virus, and the pandemic H1N1 virus. Recently, peramivir has been developed as a new neuraminidase inhibitor administered intravenously (Babu \textit{et al.}, 2000) Figure 1.4. It is currently approved for emergency use in Japan and Korea. In other countries, this drug is still undergoing clinical trials. Peramivir is based on DANA, but it contains a cyclopentane ring and has the features of both oseltamivir and zanamivir Figure 1.4. Yamashita \textit{et al.} (2010) found a new potent NA inhibitor, laninamivir considered as a second-generation acts as a long-acting NA inhibito. Administered as single inhaled dose, laninamivir is found to be effective against the wild-type strain of the influenza A and B viruses and the oseltamivir-resistant H274Y mutations of seasonal H1N1 viruses, namely, H5N1 and H1N1 (Sugaya and Ohashi, 2010; Nguyen \textit{et al.}, 2010; Yamashita, 2010).
1.8 Neuraminidase Active Site

The common feature among all influenza NAs is the active site Figure 1.5; with well formed large and rigid pockets form, can be considered as a common feature
among influenza NAs. SA and neuraminidase with conserved amino acids interact in a similar fashion with both substrate and inhibitor molecules (Xu et al., 2008; Kim et al., 1999). Therefore, antiviral drugs affecting the spread of viral replication have been developed.

The presence of four hydrophobic residues and ten Arg, Asp, and Glu residues make the neuraminidase active site highly polar (Von Itzstein and Thomson, 2009; Zhang and Xu, 2006). The active site in NA is divided into five regions from S1 to S5. S1 includes Arg 118, Arg 292, and Arg 371, which all bind to the carboxylate of substrate. S2 consists of Glu 119 and Glu 227, which are acidic residues responsible for forming the negative-charge region of the active site (Zhang and Xu, 2006). The hydrophobic region present at S3 forms at the side chains of Ile 222 and Trp 178, which are adjacent to the polar region of the Arg 152 side chain, and interacts with water molecules (Zhang and Xu, 2006; Russell et al., 2006). S4 is primarily a hydrophobic region derived from the side chains of Ile 222, Ala 246, and Arg 224. S5 has a mixed polarity and comprises of Ala 246 methyl and Glu 276 carboxylate that forms a hydrogen bond with the substrate hydroxyl group (Zhang and Xu, 2006).

The joining pockets of eight highly conserved amino acid residues are linked together, thereby causing the NA active site of these amino acids to directly come into contact with Neu5Ac and its derivatives (Von Itzstein, 2007). The active site is divided into three major pockets according to the crystal structure. Pocket 1 is formed by Glu 276, Glu 277, and Asn 294, which interact with the glycerol moiety of SA (Zhang and Xu, 2006). Pocket 2 forms a hydrophobic pocket that is not utilized by sialic acid for binding (Kim et al., 1997) and comprises the Ala 246, Ile 222, and Arg 224 side chains. Interactions with potential inhibitors are provided by these residues.
because they are highly conserved. Pocket 3 is the largest pocket consisting of numerous amino acids, such as Glu 119, Asp 151, Arg 152, Trp 178, Ser 179, Th 222, and Glu 227, all of which interact with the N-acetyl and C-4 hydroxyl groups of sialic acid (Kim et al., 1997).

Fig. 1.5 The neuraminidase active site, conserved NA residues (R118, D151, R152, R224, E227, E276, R292, and R371) (Yen et al., 2006)

1.9 Natural products

Natural products have many sources, such as microbes, plants, animals, or prebiotic origins (Vuorelaa et al., 2004). Many classes of compounds can be found in natural products. Natural products serve as natural sources of most drugs. Most of the useful therapeutic agents are derived from higher plants. In today’s clinical settings,
over 50% of all drugs are based on natural products and their analogs with 25% of such drugs containing higher plant-derived natural products (Balandrin et al., 1993).

According to WHO, around 80% of people in developing countries depend on traditional medicine for their daily healthcare (WHO, 2009). Approximately 85% of these medicines are plant extracts; whereby, around 3.5 to 4 billion people worldwide rely on natural plants as drug sources (Farnsworth, 1988). Great efforts have been exerted to discover new antiviral drugs. Many reviews have published discoveries of new natural-based drugs for treating viral infections (Khan et al., 2005; Naithani et al., 2008). Different reviews have discussed the significant role of traditional medicine in the development and use of antiviral compounds. Traditional medicines such as Chakma medicines and Ayurvedic are interestingly good sources of potential antiviral drugs (Khan et al., 2005). Many active compounds from natural sources are used as therapeutics against different functionally diverse and genetic viruses; examples of these compounds include lignans, alkaloids, thiophenes, chlorophyllins, saponins, furyl compounds, limonoids, peptides, and proteins (Chattopadhyay and Bhattacharya, 2008; Naithani et al., 2008). The mechanism of anti-viral active compounds can be explained in terms of their scavenging capacities, DNA inhibition, antioxidant activities, RNA synthesis, and inhibition of viral reproduction (Chattopadhyay and Naik, 2007).

According to several pharmacological and chemical studies, some bioactive compounds used to treat influenza are obtained from medicinal plants. Varieties of alkaloids, polyphenols, saponins, and flavonoids isolated from medicinal plants have been extensively tested for anti-influenza activity, which is reflected in the ability of
bioactive compounds to block adherence, duplication, penetration, and maturation during viral propagation (You et al., 2013).

Malaysia is home to over 15,000 species of flowering plants and more than 1,100 species of fern allies and ferns, whereby most of the plants are known as endemic plants (Napis et al., 2001). A series of chemical structures can be observed in Malaysian flora, especially in secondary flora metabolites. Malaysian plants used as medicine by locals are well documented in books and papers on ethnobotany and ethnopharmacology, with about 1,300 plant species used for medicinal purposes (Napis et al., 2001). The traditional medicines available in the markets are mostly in crude form and are sold by traditional medical practitioners. Only 100 species from high-species density available have been systematically evaluated for medicinal properties (Napis et al., 2001).

1.9.1 Family of Myrtaceae

The Myrtaceae family known as a large family of more than 5,650 species is organized in 130 to 150 genera. This family is considered as the eighth largest flowering plant family. It has centers of diversity in the wet tropics, particularly South America, Australia, and tropical Asia with occurrences in Africa and Europe (Grattapaglia et al., 2010).

The main genera are Eugenia, Syzygium, Psidium, Pimenta, Myrtus, Pseudocaryophyllus, Plinia, Leptospermum, Melaleuca, and Eucalyptus. Numerous members of this family are used in folk medicine for their antirheumatic, anti-inflammatory, antidiarrheal, antioxidant, and antimicrobial properties (Govaerts et al.,
Syzygium gaertner is considered as the largest genus of the Myrtaceae family, with approximately 1,200 species distributed in subtropical and tropical regions (Biffin et al., 2010). Some promising fruits belonging to the Syzygium genus found in Malaysia are under-utilized but are recognized to be useful for medical and nutritional purposes. A number of species from the Syzygium genus have been cultivated for their edible, colorful flesh (Rabeta et al., 2013).

1.9.1(a) Psidium guajava

1.9.1(a)(i) General introduction

Psidium guajava originated in Mexico (Rios et al., 1977) and extends throughout the South America, Europe, Africa, and Asia. Archaeological evidence shows that during pre-Columbian times, this plant was widely used and known in Peru. This plant can adapt to various climate conditions and is found in tropical and subtropical areas worldwide (Stone, 1970). Psidium guajava Linn. (Myrtaceae family) is commonly called guava, goyavier in French, goiabeiro in Portugal, banjiro in Japanese, and guaiaba in Brazil (Killion, 2000). Psidium guajava is known in Malaysian communities as jambu batu and is considered as an important food crop with medicinal use. Psidium guajava is a small, thin tree with a height of 10 m and a smooth peeling bark. It has a short petiolate leaves that are 5-15 cm long. Its flowers have whitish petals measuring up to 20 cm long as well as numerous stamens. The fruit is pear-shaped, small, 3-6 cm long and reddish-yellow when ripe (Stone, 1970). The Psidium guajava plants are shown in Figure 1.6.
Fig. 1.6 *Psidium guajava* plants (a) flower, (b) fruit, (c) leaves and (d) tree (Finca Tropical 2011)

1.9.1(a)(ii) **Traditional medicinal uses of *Psidium guajava***

*P. guajava* was traditionally used as an anti-diarrheal agent and to treat dysentery. Its use as antioxidant, lipid lowering agent, and anti-bacterial agent and its hypoglycemic activities have also been reported (Rahmat *et al.*, 2004). *P. guajava* is used in many parts of the world to treat different diseases and conditions, such as fever, pain, wounds, caries, inflammation, and diabetes, as reported in many ethno-pharmacological studies (Table 1.1).
Table 1.1: Ethnomedical uses of *Psidium guajava*.

<table>
<thead>
<tr>
<th>Place, country</th>
<th>Part(s) used</th>
<th>Ethno medical uses</th>
<th>Preparation(s)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaysia</td>
<td>Leaves</td>
<td>Vomiting, diarrhea and stomach ache</td>
<td>Maceration</td>
<td>Alsarhan <em>et al.</em>, 2010</td>
</tr>
<tr>
<td>Panama, Cuba, Costa Rica, M´exico, Nicaragua, Panam´a, Per´u, Venezuela, Mozambique, Guatemala, Argentina</td>
<td>Leaves</td>
<td>anti-inflammatory</td>
<td>Externally applied hot on inflammations</td>
<td>M´endez, 1990; Valdiz´an and Maldonado, 1972</td>
</tr>
<tr>
<td>Kinshasa, Congo</td>
<td>Leaves, bark</td>
<td>Diarrhoea, antiamoebic</td>
<td>Infusion or decoction tisane</td>
<td>Tona <em>et al.</em>, 1999</td>
</tr>
<tr>
<td>Latin America, Mozambique</td>
<td>Leaves</td>
<td>Diarrhoea, stomach ache</td>
<td>Infusion or decoction</td>
<td>Pontikis, 1996</td>
</tr>
<tr>
<td>South Africa</td>
<td>Leaves</td>
<td>Diabetes mellitus, hypertension</td>
<td>Infusion or decoction</td>
<td>Oh <em>et al.</em>, 2005; Ojewole, 2005</td>
</tr>
<tr>
<td>China</td>
<td>Leaves</td>
<td>Diarrhoea, antiseptic, Diabetes mellitus</td>
<td>Infusion or decoction</td>
<td>Teixeira <em>et al.</em>, 2003</td>
</tr>
<tr>
<td>Brazil</td>
<td>Ripe fruit, flowers, and leaves</td>
<td>Anorexia, cholera, diarrhoea, digestive problems, dysentery, gastric insufficiency, inflamed mucous membranes, laryngitis, mouth (swelling), skin problems, sore throat, ulcers, vaginal discharge</td>
<td>Mashed, Decoction</td>
<td>Holetz <em>et al.</em>, 2002; Cybele <em>et al.</em>, 1995</td>
</tr>
</tbody>
</table>
P. guajava contains many phytochemicals including essential oils, polysaccharides, vitamins (Macleod and Troconis, 1975; Smith and Siwatibau, 1975), triterpenoid acid and sesquiterpenoid alcohols (Begum et al., 2002; Wilson and Shaw, 1978), saponins, flavonoids, steroids, tannins, glycosides, alkaloids, (Geidam et al., 2007; Narayana et al., 2001; Cho et al., 2003). P. guajava is very rich in vitamins and antioxidants and also has a high content of lycopene, lutein and zeaxanthine (Hobert and Tietze, 1998; Tee et al., 1997). The P. guajava fruit has high water content and low amounts of proteins, fats, and carbohydrates. This fruit also contains thiamine, iron, niacin, manganese, and vitamins A and C. Ascorbic acid is the major constituent of its skin (Gutierrez et al., 2008).

Different compounds were isolated from fruits and leave of P. guajava such as gallic acid (1), protocatechuic acid (2), (Okuda et al., 1984) caffeic acid (Liang et al., 2005) (3), ferulic acid (Zhu et al., 1997) (4), chlorogenic acid (Liang et al., 2005) (5), ellagic acid (Misra and Seshadri, 1968) (6), quercetin (Liang et al., 2005) (7), leucocyanidin (Nadkarni and Nadkarni, 1999) (8), kaempferol (Liang et al., 2005) (9), quercetin 3-β-galactoside (Liang et al., 2005) (10), kaempferol 3-β-glucoside (Liang et al., 2005) (11), guaijaverin (Prabu et al., 2006) (12), morin-3-O-α-L-arabinopyranoside (Arima and Danno, 2002) (13), meco cyanin (Liang et al., 2005) (14), quercitrin (Liang et al., 2005) (15), zeatin riboside (Nagar and Rao, 1981) (16), oeanolic acid (Siddiqui et al., 2002) (17), ursolic acid (Begum et al., 2002) (18), β-sitosterol (Begum et al., 2002) (19), uvaol (Begum et al., 2004) (20), goreishic acid I (Begum et al., 2002) (21), 2-α-hydroxyursolic acid (Begum et al., 2002) (22),
guavanoic acid (Begum et al., 2004) (23), guavacoumaric acid (Begum et al., 2002) (24), guajavolide (Begum et al., 2004) (25), 2α-hydroxy-3β-P-E-coumaroyloxyurs-12,18-dien-28-oic acid (Begum et al., 2002) (26), α-sitosterol-3-O-β-D-glucopyranoside (Begum et al., 2002) (27).
1.9.1(a)(iv) Essential oil of *Psidium guajava*

Analysis of essential oils from *Psidium guajava* (fruit and leaves) using GC and GC-MS enabled the identification of different constituents varied from Monoterpenes and Sesquiterpenes. Essential oils are extracted from the fruit, leaves, and seeds of *P. guajava*. The yield and composition of the obtained oils vary from one part to another. Monoterpene hydrocarbon *E*-β-Ocimene, (Li et al., 1999) (28), Z-β-Ocimene (Li et al., 1999) (29), Myrcene (Li et al., 1999) (30), p-cymene (Kenneth et al., 1970) (31), α-pinene (Kenneth et al., 1970) (32), β-pinene (Jordan et al., 2003) (33), camphene (Jordan et al., 2003) (34), γ-terpinene (Jordan et al., 2003) (35) identified from leaves and fruits with different composition. Oxygenated monoterpenes identified from seed and leaves including 1,8-cineole (Kenneth et al., 1970) (36), citronellol (Kenneth et al., 1970) (37), linalool (Kenneth et al., 1970) (38), limonene (Kenneth et al., 1970) (39). Sesquiterpenes hydrocarbon from bark, leaves and fruits include α-copaene (Oliver-Bever, 1986) (40), β-copaene (Adam et al., 2011) (41), 1-epi-cubenol (Ruther, 2000) (42), α-cubebene (Porat et al., 2001) (43), α-selinene (Ruther, 2000) (44), α-Humulene (Paniandy et al., 2000) (45) β-caryophyllene (Adam et al., 2011) (46), γ-cadinene (Ruther, 2000) (47), germacrene D (Oliver-Bever, 1986) (48). Another important constituent oxygenated sesquiterpenes identified with GC-MS from leaves and fruits showed different composition include spathulenol (Porat et al., 2001) (59), ar-turmerone (Paniandy et al., 2000) (50), δ-cadinol (Ruther, 2000) (51), α-cadinol (Oliver-Bever, 1986) (52), caryophyllene oxide (Ruther, 2000) (53), humulene epoxide II (Paniandy et al., 2000) (54).